Drug intelligence / Profile preview

Niguldipine

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Overview

Niguldipine is a calcium channel blocker with α1-adrenergic antagonist properties. It was investigated by Eli Lilly and Company for the treatment of hypertension but was discontinued.

Other names: NiguldipinoNiguldipinum

Targets

ADRA1A (α1A)LTCC (Voltage-gated calcium channel (L-type))ADRA1B (α1B)

Beyond the preview

Go deeper on Niguldipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niguldipine.

Explore the full profile